skip navigation links
National Cancer Institute
Enterprise Vocabulary Services
Box
NCIm Version: 201808 (Browser Version 2.9, using LexEVS 6.5.1)
SearchBox Top
SearchBox Bottom
Thalidomide (CUI C0039736) Suggest changes to this concept
Add to Cart

Terms & Properties

Concept Unique Identifier (CUI): C0039736

NCI Thesaurus Code: C870  (see NCI Thesaurus info)

Semantic Type: Organic Chemical

Semantic Type: Pharmacologic Substance

Semantic Type: Hazardous or Poisonous Substance

NCIt Definition: A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties. Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons. This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis. In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.

MSH Definition: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.

PDQ Definition: A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties. Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons. This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis. In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis. Check for active clinical trials using this agent. (NCI Thesaurus)

NCI-GLOSS Definition: A drug that is used to treat multiple myeloma in patients who have just been diagnosed, and a painful skin disease related to leprosy. It is also being studied in the treatment of other types of cancer. Thalomid belongs to the family of drugs called angiogenesis inhibitors.

CSP Definition: piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn due to teratogenic effects; it has been reintroduced and used for a number of immunological and inflammatory disorders.

NPO Definition: A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties. Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons. This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis. In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.

Synonyms & Abbreviations: (see Synonym Details)
(+)-Thalidomide
(+-)-N-(2,6-dioxo-3-Piperidyl)phthalimide
(+-)-Thalidomide
(-)-Thalidomide
(±)-N-(2,6-dioxo-3-piperidyl)phthalimide
(±)-thalidomide
.alpha.-Phthalimidoglutarimide
1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline
1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-
2, 6-Dioxo-3-phthalimidopiperidine
2,6-dioxo-3-phthalimidopiperidine
2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione
2-(2,6-dioxopiperidin-3-yl) isoindoline-1,3-dione [source: IUPAC]
3-Phthalimidoglutarimide
48832
50-35-1
66847
91729
alpha-(N-Phthalimido)glutarimide
alpha-N-Phthalylglutaramide
alpha-Phthalimidoglutarimide
Celgene Brand of Thalidomide
Contergan
Distaval
K-17
Kevadon
N-(2,6-dioxo-3-piperidyl)phthalimide
N-Phthaloylglutamimide
N-Phthalyl-glutaminsaeure-imid
N-Phthalylglutamic acid imide
Neurosedyn
Pantosediv
Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (+)-
Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (-)-
Pro-ban M
Product containing thalidomide (medicinal product)
Product containing thalidomide
Sedalis
Sedoval K-17
Softenon
Synovir
Talidomida
Talimol
Thalidomide (substance)
Thalidomide [Chemical/Ingredient]
thalidomide
Thalidomidum
Thalomid
THAL
α-(N-phthalimido)glutarimide
α-N-phthalylglutaramide
α-phthalimidoglutarimide

External Source Codes: 
NCI Thesaurus Code C870 (see NCI Thesaurus info)
CAS Registry Number 50-35-1 (see NLM ChemIDplus info)
FDA UNII Code 4Z8R6ORS6L
NSC Code 66847 (see NCI DTP info)
PDQ Closed Trial Search ID 42332
PDQ Open Trial Search ID 42332 (check for NCI PDQ open clinical trial info)

Other Properties: Property Definitions
Name Value Source
Accepted_Therapeutic_Use_For Aphthous stomatitis; Crohns disease; cutaneous manifestations of erythema nodosum leprosum; GVHD; HIV-associated wasting syndrome; Karposi sarcoma; lepromatous leprosy; multiple myeloma; mycobacterium tuberculosis and nontuberculosis; primary brain tumors NCI
ACTIVE 1 SNOMEDCT_US
AQL AA AD AE AG AI AN BL CF CH CL CS CT EC HI IM IP ME PD PK PO RE SD ST TO TU UR MSH
CASE_SIGNIFICANCE_ID 900000000000448009 SNOMEDCT_US
CHARACTERISTIC_TYPE_ID 900000000000011006 SNOMEDCT_US
CHEBI_ID CHEBI:9513 NCI
Chemical_Formula C13H10N2O4 NCI
CODE NPO_434 NPO
Contributing_Source CTRP NCI
Contributing_Source FDA NCI
CTV3ID XUaAd SNOMEDCT_US
CTV3ID XUKz0 SNOMEDCT_US
DATE_LAST_MODIFIED 2006-05-10 PDQ
DB_XR_ID NCIT: C870 NPO
DC 1 MSH
DEFINITION_STATUS_ID 900000000000074008 SNOMEDCT_US
DID 0397-6187 CSP
DX 19660101 MSH
EFFECTIVE_TIME 20020131 SNOMEDCT_US
EFFECTIVE_TIME 20040131 SNOMEDCT_US
FDA_UNII_CODE 4Z8R6ORS6L DRUGBANK
FDA_UNII_CODE 4Z8R6ORS6L NDFRT
LEVEL Example Part D Eligible Drugs USPMG
LEVEL Ingredient NDFRT
LT TRD MSH
LT TRD MTH
LT TRD PDQ
MDA 19990101 MSH
MESH_DEFINITION A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action. NDFRT
MESH_DUI D013792 NDFRT
MESH_NAME Thalidomide NDFRT
MESH_UI M0021267 NDFRT
MMR 20160601 MSH
MN D02.241.223.805.810.800 MSH
MN D03.383.621.808.800 MSH
MN D03.633.100.513.750.750 MSH
MODIFIER_ID 900000000000451002 SNOMEDCT_US
NCI_THESAURUS_CODE C870 PDQ
NDFRT_KIND DRUG_KIND NDFRT
NDFRT_KIND INGREDIENT_KIND NDFRT
NUI N0000006367 NDFRT
NUI N0000148588 NDFRT
ORIG_STY Drug/agent PDQ
PA D007166 MSH
PA D007917 MSH
PA D013723 MSH
PA D020533 MSH
PID 5584 PDQ
RDF_ID NPO_434 NPO
RN 0 MSH
RN 4Z8R6ORS6L MSH
RR 50-35-1 (Thalidomide) MSH
RXAUI 1183847 RXNORM
RXAUI 2074750 RXNORM
RXAUI 2994590 RXNORM
RXAUI 3091937 RXNORM
RXAUI 3244293 RXNORM
RXAUI 3244294 RXNORM
RXAUI 3247902 RXNORM
RXAUI 3247903 RXNORM
RXAUI 333522 RXNORM
RXCUI 10432 RXNORM
RXCUI 220239 RXNORM
RXN_BN_CARDINALITY single RXNORM
SID APRD01251 DRUGBANK
SOS Anticancer Drug Directed Against Endothelial Growth Factor Receptor NPO
SPL_SET_ID 2eda833b-1357-4ed4-a093-194524fcb061 MTHSPL
SUBSET_MEMBER 900000000000497000~MAPTARGET~XUaAd SNOMEDCT_US
SUBSET_MEMBER 900000000000497000~MAPTARGET~XUKz0 SNOMEDCT_US
SUBSET_MEMBER 900000000000508004~ACCEPTABILITYID~900000000000548007 SNOMEDCT_US
SUBSET_MEMBER 900000000000508004~ACCEPTABILITYID~900000000000549004 SNOMEDCT_US
SUBSET_MEMBER 900000000000509007~ACCEPTABILITYID~900000000000548007 SNOMEDCT_US
SUBSET_MEMBER 900000000000509007~ACCEPTABILITYID~900000000000549004 SNOMEDCT_US
TERMUI T040492 MSH
TERMUI T620243 MSH
TERMUI T620244 MSH
TH BAN (19XX) MSH
TH FDA SRS (2014) MSH
TH INN (19XX) MSH
TH NLM (2006) MSH
TH USAN (1961) MSH
TH USP (19XX) MSH
TH US MSH
TYPE_ID 900000000000003001 SNOMEDCT_US
TYPE_ID 900000000000013009 SNOMEDCT_US
VANDF_RECORD 50.416^3806^Active/Master NDFRT
VANDF_RECORD 50.6^3529^Active/Master NDFRT
VUID 4021134 NDFRT

Additional Concept Data:  (none)

URL to Bookmark: https://ncim-stage.nci.nih.gov/ncimbrowser/ConceptReport.jsp?dictionary=NCI Metathesaurus&code=C0039736

Mainbox Bottom